A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Launched by INNOVENT BIOLOGICS (SUZHOU) CO. LTD. · Dec 1, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
• • 2. Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)
• Exclusion Criteria:
• • 1. History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
• • 2. Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
• • 3. Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent
• • 4. Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent
• • 5. Has received any conventional therapeutic agent within 1 months of the first administration of study agent
• • 6. Has received any topic therapeutic agent within 2 weeks of the first administration of study agent